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to prevent healthcare-associated
infectionWorldwide, millions of patients are affected annually by
healthcare-associated infection (HCAI), impacting up to 80,000
patients in European hospitals on any given day.1 This repre-
sents not only a public health risk, but also an economic burden.
Through its Cooperation in Science and Technology pro-
gramme (COST), the European Commission has recently funded
a four-year initiative to establish a network of stakeholders
involved in development, regulation, and use of novel anti-
microbial coatings for prevention of HCAI. The network (its
acronym is AMiCI) currently comprises participants of more
than 60 universities, knowledge institutes, and companies
across 29 European countries and, to date, represents the most
comprehensive grouping to target use of these emergent
technologies in healthcare settings. By accessing the network’s
website (http://www.amici-consortium.eu), there is an
ongoing opportunity for those interested to engage with the
programme.
Antimicrobial coatings hold promise based, in essence, on
the application of materials and chemicals with persistent
bactericidal or bacteriostatic properties on to surfaces in
healthcare environments.2,3 However, an excellent systematic
review of the topic was published recently in this journal in
which the authors reported a scarcity of studies assessing non-
copper antimicrobial surfaces in the clinical environment, and
a complete lack of published data regarding the successful
implementation of materials other than copper on clinically
significant outcomes (including HCAI).4
The focus of considerable commercial investment and aca-
demic research energies, such antimicrobial coating-based ap-
proaches are widely believed to have potential to reduce
microbial numbers on surfaces in clinical settings.5 This belief is
despite limited definitive evidence for their efficacy in clinical
settings; rather, it is based largely on positive findings from
studies involving, for example, silver or gold ions, titanium or
organosilane, under laboratory conditions.6 However, there are
reports of successful delay and/or prevention of recontamination
following conventional cleaning and disinfection by problematic
micro-organisms, including meticillin-resistant Staphylococcus
aureus and vancomycin-resistant enterococci.7e10
The European Commission funding of this network reflects
the potential for antimicrobial innovations to positively impacthttp://dx.doi.org/10.1016/j.jhin.2016.12.012
0195-6701/ª 2016 The Healthcare Infection Society. Published by Elsevieron the four million patients reported by the European Centre
for Disease Prevention and Control to be affected by HCAI
annually. More specifically, the network participants will
address knowledge gaps that persist due to lack of:
e systematic, international co-ordinated research on the
effects (both positive and negative) of antimicrobial
coatings in healthcare or other sectors;
e know-how regarding the availability and use of different
mechanisms of action of (nano)-coatings and the desired
use in different applications, procedures, and products;
e information relating to the possible adverse effects of such
materials, e.g. the potential induction of new resistance
mechanisms in bacteria or emission of toxic agents into the
environment;
e standard performance assessments for antimicrobial coat-
ings, applicable in laboratory settings and, thereby,
complicating direct comparison of different coatings from
different producers;
e standard performance assessments to determine func-
tionality of coatings in normal and extreme test conditions,
field tests, or benchmark methods to assess the efficacy in
field conditions; and
e communication or publication of best practices by hospi-
tals, other clinical facilities, regulators or product
suppliers.
The project recognizes, and aims to address, the disparate
perspectives of inventors and entrepreneurs; academic re-
searchers; manufacturers; distributors; commercial, clinical,
biocide, and consumer affairs regulators; medicines agencies;
clinical microbiologists; attending physicians; healthcare fa-
cility managers and procurement officers; environmental
monitoring specialists and environmental protection agencies;
hygiene companies; and, of course, patients and their carers.
The AMiCI consortium is addressing this challenging diversity of
viewpoints through a series of consultation events and targeted
transfer of personnel between industry and academic groups,
strategically chosen to deal with the most pressing topics
arising from those consultations, and the development of
coatings capable of demonstrably reducing HCAI.
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